Dr. Gordon on Immunotherapy Treatment for Osteosarcoma

Nancy B. Gordon, MD
Published Online: Friday, Feb 17, 2017



Nancy B. Gordon, MD, assistant professor, department of pediatrics, The University of Texas MD Anderson Center, discusses immunotherapy treatments for osteosarcoma.

Pulmonary metastases are one of the main causes of death for patients with osteosarcoma, Gordon explains. Immunotherapy for osteosarcoma has shown benefits in different aspects. There has been treatment that has been delivered through cytokines, such as interleukin-2, that has particularly been effective.

If you give a patient an antibody against PD-1, a patient can see a therapeutic benefit in osteosarcoma, Gordon states.
 


Nancy B. Gordon, MD, assistant professor, department of pediatrics, The University of Texas MD Anderson Center, discusses immunotherapy treatments for osteosarcoma.

Pulmonary metastases are one of the main causes of death for patients with osteosarcoma, Gordon explains. Immunotherapy for osteosarcoma has shown benefits in different aspects. There has been treatment that has been delivered through cytokines, such as interleukin-2, that has particularly been effective.

If you give a patient an antibody against PD-1, a patient can see a therapeutic benefit in osteosarcoma, Gordon states.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Optimizing Treatment and Management of Soft Tissue Sarcoma in Community OncologyNov 30, 20171.5
Publication Bottom Border
Border Publication
$emailPop$